SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Regeneron logo on a light brown building
Pharm Country
Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
April 15, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illumina signage outside its office in California
Policy
EC Approves Illumina’s Plan to Divest Cancer Diagnostics Maker Grail
After a years-long antitrust battle, the European Commission on Friday approved Illumina’s plans to divest Grail. However, Illumina said while there is “an agreement with the EC on specific divestment options” that “does not mean the method of divestment has been finalized.”
April 12, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
For the second time in as many years, the FDA has hit Supernus Pharmaceuticals with a Complete Response Letter, citing undisclosed quality and master filing issues for the drug-device combination.
April 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Entrance to the FTC's office in Washington, DC
Deals
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy
The FTC and the U.S. Department of Justice’s antitrust division will have another 30 days to examine Novo Nordisk Foundation’s acquisition of contract manufacturer Catalent, according to an SEC filing.
April 5, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: Merck KGaA signage at its headquarters in Darmstadt, Germany
Business
Merck KGaA, Caris Sign Potential $1.4B Deal to Develop First-in-Class ADCs for Cancer
Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.
April 4, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Collage of a dragon, congress, and money
Policy
Companies Detail Potential Fallout as Pressure on WuXi AppTec Builds
Three Biopharma firms disclosed concerns about how emerging geopolitical tensions between the U.S. and China might impact their business with the contract manufacturer.
April 4, 2024
 · 
3 min read
 · 
Tyler Patchen
Pictured: The exterior of Sutro Biopharma's headquarters in South San Francisco
Drug Development
Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
Under the agreement, Ipsen nabs exclusive global rights for development and commercialization of Sutro Biopharma’s STRO-003, an antibody-drug conjugate which is completing the final stages of preclinical development.
April 2, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Exterior of an FDA building
Policy
Fractyl Secures FDA Approval for Weight Maintenance Study After Discontinuation of GLP-1s
Fresh from its IPO, Fractyl Health got an Investigational Device Exemption from the FDA, clearing a pivotal study of its Revita system to help maintain weight loss following the discontinuation of GLP-1 drugs.
April 1, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Gamida Cell is moving forward with a sig
Deals
Gamida Restructures Under Ownership of Highbridge Capital Management
Gamida Cell, whose cell therapy for blood cancer was approved last year by the FDA, is being taken private and restructuring due to liquidity constraints.
March 29, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: An aerial view of the former Roche manuf
Deals
What Lonza’s $1.2B Buy of Roche Biologics Plant Means for CDMO Market
The Swiss contract manufacturer’s cash deal for Roche’s facility in Vacaville, California, is one of the world’s largest manufacturing sites for biologics—a major growth driver for Lonza and other CDMOs.
March 28, 2024
 · 
5 min read
 · 
Tyler Patchen
Pictured: 3d illustration of hepatitis B viruses i
Drug Development
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
Altimmune on Wednesday said it is ending development of HepTcell, a hepatitis B candidate, following disappointing trial results as it focuses on obesity and metabolic dysfunction-associated steatohepatitis.
March 28, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: MRI images of the brain for neurological
Drug Development
Stoke Announces $125M Public Offering on Heels of Positive Data for Epilepsy Drug
Stoke Therapeutics plans to offer up more than 5.5 million shares of its common stock following positive Phase I/IIa data for its Dravet syndrome candidate.
March 28, 2024
 · 
1 min read
 · 
Tyler Patchen
Pictured: PET scan of the brain iStock/wehnt
Drug Development
Novocure Gets Phase III Win in Patients with Brain Metastases from Lung Cancer
Novocure’s stock spiked more than 15% Wednesday morning after the company announced its Tumor Treating Fields therapy met the primary endpoint in a late-stage trial.
March 27, 2024
 · 
3 min read
 · 
Tyler Patchen
Merck Research Laboratories headquarters in Silicon Valley
FDA
FDA Approves Potential ‘Game Changer’ for Pulmonary Arterial Hypertension
Merck’s Winrevair is the second PAH drug to get the FDA’s green light in the past week, following Johnson & Johnson’s Opsynvi, which won approval on Friday.
March 26, 2024
 · 
4 min read
 · 
Tyler Patchen
Pictured: Aerial panorama of Botafogo Bay and Suga
Drug Delivery
Brazil and Caring Cross to Produce Affordable CAR-T, Stem Cell Gene Therapies
Brazil’s Ministry of Health and nonprofit Caring Cross announced a collaboration Tuesday aimed at local manufacturing of CAR-T cell and stem cell gene therapies at a much lower cost than Europe and the U.S.
March 26, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More